Spago Nanomedical AB (SPAGO) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.201x

Based on the latest financial reports, Spago Nanomedical AB (SPAGO) has a cash flow conversion efficiency ratio of -0.201x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-6.19 Million ≈ $-665.71K USD) by net assets (Skr30.75 Million ≈ $3.31 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Spago Nanomedical AB to measure how much of total assets are equity-financed.

Spago Nanomedical AB - Cash Flow Conversion Efficiency Trend (2011–2025)

This chart illustrates how Spago Nanomedical AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Spago Nanomedical AB total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.

Spago Nanomedical AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Spago Nanomedical AB ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Batero Gold Corp
V:BAT
-0.003x
Aqua Metals Inc
NASDAQ:AQMS
-0.293x
JATCORP LTD.
F:3J2
N/A
Burford Capital Limited
LSE:BUR
0.048x
Techstep ASA
OL:TECH
0.098x
Courtois S.A
PA:COUR
-0.010x
Immuron Ltd
AU:IMC
-0.189x
Kore Mining Ltd
V:KORE
0.029x

Annual Cash Flow Conversion Efficiency for Spago Nanomedical AB (2011–2025)

The table below shows the annual cash flow conversion efficiency of Spago Nanomedical AB from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see Spago Nanomedical AB (SPAGO) market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 Skr30.75 Million
≈ $3.31 Million
Skr-28.30 Million
≈ $-3.05 Million
-0.920x +11.77%
2024-12-31 Skr33.23 Million
≈ $3.58 Million
Skr-34.67 Million
≈ $-3.73 Million
-1.043x +4.03%
2023-12-31 Skr41.32 Million
≈ $4.45 Million
Skr-44.91 Million
≈ $-4.83 Million
-1.087x -461.18%
2022-12-31 Skr197.16 Million
≈ $21.22 Million
Skr-38.19 Million
≈ $-4.11 Million
-0.194x -0.64%
2021-12-31 Skr184.81 Million
≈ $19.89 Million
Skr-35.57 Million
≈ $-3.83 Million
-0.192x -63.76%
2020-12-31 Skr159.67 Million
≈ $17.18 Million
Skr-18.77 Million
≈ $-2.02 Million
-0.118x +24.02%
2019-12-31 Skr137.63 Million
≈ $14.81 Million
Skr-21.29 Million
≈ $-2.29 Million
-0.155x -79.87%
2018-12-31 Skr122.22 Million
≈ $13.15 Million
Skr-10.51 Million
≈ $-1.13 Million
-0.086x -19.90%
2017-12-31 Skr107.78 Million
≈ $11.60 Million
Skr-7.73 Million
≈ $-831.87K
-0.072x +34.47%
2016-12-31 Skr71.84 Million
≈ $7.73 Million
Skr-7.86 Million
≈ $-846.18K
-0.109x -33.92%
2015-12-31 Skr65.41 Million
≈ $7.04 Million
Skr-5.34 Million
≈ $-575.21K
-0.082x +23.04%
2014-12-31 Skr56.05 Million
≈ $6.03 Million
Skr-5.95 Million
≈ $-640.53K
-0.106x +47.60%
2013-12-31 Skr38.18 Million
≈ $4.11 Million
Skr-7.74 Million
≈ $-832.62K
-0.203x -1324.77%
2012-12-31 Skr42.25 Million
≈ $4.55 Million
Skr-601.00K
≈ $-64.68K
-0.014x +33.80%
2011-12-31 Skr12.84 Million
≈ $1.38 Million
Skr-276.00K
≈ $-29.70K
-0.021x --

About Spago Nanomedical AB

ST:SPAGO Sweden Biotechnology
Market Cap
$8.33 Million
Skr77.40 Million SEK
Market Cap Rank
#27505 Global
#600 in Sweden
Share Price
Skr0.12
Change (1 day)
+0.43%
52-Week Range
Skr0.09 - Skr0.33
All Time High
Skr19.04
About

Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well… Read more